Antibiotic susceptibility of Helicobacter pylori in Iceland

References

• Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in chronic gastritis. Lancet. 1983;321:1273–1275.
   Google Scholar
• Vale FF, Vítor JMB. Transmission pathway of Helicobacter pylori: does food play a role in rural and urban areas? Int J Food Microbiol. 2010;138:1–12.
   PubMed Web of Science ®Google Scholar
• Logan RPH, Walker MM. ABC of the upper gastrointestinal tract: epidemiology and diagnosis of Helicobacter pylori infection. BMJ. 2001;323:920–922.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449–1461.
   PubMed Web of Science ®Google Scholar
• Infection with Helicobacter pylori. In IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. IARC monographs on the evaluation of carcinogenal risks to human. Schistosomes, liver, flukes and Helicobacter pylori. Lyon, France. International Agency for Research on Cancer. 1994;61:177–240.
   Google Scholar
• Eidt S, Stolte M, Fischer R. Helicobacter pylori gastritis and primary gastric non-Hodgkin’s lymphomas. J Clin Pathol. 1994;47:436–439.
   PubMed Web of Science ®Google Scholar
• Fischbach W. Gastric MALT lymphoma – update on diagnosis and treatment. Best Pract Res Clin Gastroenterol. 2014;28:1069–1077.
   PubMed Web of Science ®Google Scholar
• McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010;362:1597–1604.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Mégraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Recent advances in clinical practice Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409–414.
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Mégraud F, Lopez-Brea M, et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20:820–823.
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Verspoten A, on behalf of the Study Group participants, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.
   PubMed Web of Science ®Google Scholar
• Smith SM, O´Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. WJG. 2014;20:9912–9921.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bazzoli F, Delchier JC, Pylera Study, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905–913.
   PubMed Web of Science ®Google Scholar
• Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39:1001–1005.
   PubMedGoogle Scholar
• Chen PY, Wu MS, Chen CY, Taiwan Gastrointestinal Disease and Helicobacter Consortium, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;44:427–437.
   PubMed Web of Science ®Google Scholar
• Larsen AL, Ragnhildstveit E, Moayeri B, et al. Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway. APMIS. 2013;121:353–358.
   PubMed Web of Science ®Google Scholar
• Storskrubb T, Aro P, Ronkainen J, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006;11:224–230.
   PubMed Web of Science ®Google Scholar
• Petersen AM, Gjøde P, Vinge OD, et al. Helicobacter pylori antimicrobial resistance and risk factors in Denmark 1998–2004: no need for concern? Helicobacter. 2006;11:210–211.
   PubMed Web of Science ®Google Scholar
• Koivisto TT, Rautelin HI, Voutilainen ME, et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther. 2004;19:1009–1017.
   PubMed Web of Science ®Google Scholar
• Nilsson F, Walden M. Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance. Lakartidningen. 1999;96:460–463.
   PubMedGoogle Scholar
• Jaup BH, Brandberg A, Stenquist B, et al. Antibiotic resistance among strains of Helicobacter pylori in Gothenburg. Bacteria resistant to metronidazole. Lakartidningen. 1998;95:279–281.
   PubMedGoogle Scholar
• Kostamo P, Veijola L, Oksanen A, et al. Recent trends in primary antimicrobial resistance of Helicobacter pylori in Finland. Int J Antimicrob Agents. 2011;37:22–25.
   PubMed Web of Science ®Google Scholar
• Gunnarsdottir AI, Gudjonsson H, Kristinsson KG, et al. Lyfjanæmi Helicobacter pylori á Íslandi (The antibiotic susceptibility of Helicobacter pylori in Iceland). Icelandic Med J. 1998;suppl. 36:32. abstract.
   Google Scholar
• bioMérieux. E-test® Application Guide [Internet]; [cited 2013 Mar 29]. Available from: http://www.biomerieux-usa.com/upload/Supplementary_Inserts_-_16273_-B_-en_-EAG_- Etest_Application_Guide-3.pdf; 2012.
   Google Scholar
• Roberts SE, Morrison-Rees S, Samuel DG, et al. Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment Pharmacol Ther. 2016;43:334–345.
   PubMed Web of Science ®Google Scholar
• Andreasson A, Talley NJ, Engstrand L, et al. The prevalence of Helicobacter pylori positivity in the general population in Sweden has decreased from 38 per cent to 16 per cent since 1989. Sweden: Stress Research Institute, Stockholms Universitet. Available from: http://www.stressforskning.su.se/polopoly_fs/1.238715.1433421196!/menu/standard/file/Anna%20Oktober%202014_1_liggande.pdf.
   Google Scholar
• Dahlerup S, Andersen RC, Nielsen BS, et al. First-time urea breath tests performed at home by 36,629 patients: a study of Helicobacter pylori prevalence in primary care. Helicobacter. 2011;16:468–474.
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Broutet N, Cantagrel A, et al. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2002;21:549–552.
   PubMed Web of Science ®Google Scholar
• Hachem CY, Clarride JE, Reddy R, et al. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis. 1996;24:37–41.
   PubMed Web of Science ®Google Scholar
• Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109:1595–1602.
   PubMed Web of Science ®Google Scholar
• Karpiński TM, Andrzejewska E, Eder P, et al. Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. Acta Microbiol Immunol Hung. 2015;62:287–293.
   PubMed Web of Science ®Google Scholar
• DeFrancesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother. 2007;59:783–785.
   PubMed Web of Science ®Google Scholar
• Boyanova L, Nikolov R, Gergova G, et al. Two-decade trends in primary Helicobacter pylori resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010;67:319–326.
   PubMed Web of Science ®Google Scholar